Fiche société
Kite, A Gilead Company
Traitements, essais et publications liés.
Traitements13programmes
Essais8liés
Publications26liées
SourceDBlocale
Traitements
13| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| anito-celThe goal of this clinical study is to learn more about the study drug Anitocabtagene autoleucel (anito-cel), and its safety, tolerability, dosing, and preliminary effectiveness in participants with generalized myasthenia gravis (GMG). Anito-cel is a B-cell maturation antigen (BCMA)-directed CAR-T cell therapy. The primary objective of this study is to assess the safety profile, including any dose-limiting toxicity (DLT) and identification of a maximum tolerated dose (MTD) (if applicable), to support selection of the recommended Phase 2 dose (RP2D) of anito-cel when administered to participants with GMG. | Myasthénie, Myopathies | Phase 1 | Thérapie cellulaire | United States | À vérifier |
| brexucabtagene autoleucelThe primary objective of this study is to evaluate the safety and tolerability of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory chronic lymphocytic leukemia (r/r CLL) and small lymphocytic lymphoma (r/r SLL) who have received at least 2 prior lines of treatment, one of which must include a Bruton's tyrosine kinase (BTK) inhibitor. After the end of KTE-C19-108, participants who received an infusion of brexucabtagene autoleucel will complete the remainder of the 15-year follow-up assessments in a separate Long-term Follow-up study, KT-US-982-5968 (NCT05041309). | SEP | Phase 1 | Immunomodulation | United States, Italy | À vérifier |
| CyclophosphamideThis randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. | Cancer, Épilepsie, Insuffisance cardiaque, Lupus, Myasthénie, Myopathies, Sclérose latérale amyotrophique, SEP | Phase 1 | À vérifier | United States | À vérifier |
| FludarabineThe purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases. The trial anticipates enrolling participants to reach a maximum of 24 participants who will receive 1 dose of KYV-101 and will be followed for 2 years. | Cancer, Lupus, Myasthénie, Myopathies, SEP | Phase 1 | Immunomodulation + Thérapie cellulaire | United States | À vérifier |
| KITE-363This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases. The primary objectives of this study are: * To evaluate the safety and tolerability of KITE-363 in participants with autoimmune neurologic diseases * To determine the recommended dose for Phase 1b. * To evaluate the preliminary efficacy of KITE-363 in participants with autoimmune neurologic diseases. | Lupus, Myasthénie, SEP | Phase 1 | United States, Australia, Canada | À vérifier | |
| CyclophosphamideThis randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. | Lupus | NA | À vérifier | Brazil | À vérifier |
| KITE-363This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases. The primary objectives of this study are: * To evaluate the safety and tolerability of KITE-363 in participants with autoimmune neurologic diseases * To determine the recommended dose for Phase 1b. * To evaluate the preliminary efficacy of KITE-363 in participants with autoimmune neurologic diseases. | Myasthénie | Phase 1 | United States, Australia, Canada | À vérifier | |
| CyclophosphamideThis randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. | Cancer | Phase 2 | Thérapie cellulaire | United States | À vérifier |
| CyclophosphamideThis randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. | Sclérose latérale amyotrophique | Phase 2 | À vérifier | À vérifier | |
| KITE-363This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases. The primary objectives of this study are: * To evaluate the safety and tolerability of KITE-363 in participants with autoimmune neurologic diseases * To determine the recommended dose for Phase 1b. * To evaluate the preliminary efficacy of KITE-363 in participants with autoimmune neurologic diseases. | Lupus | Phase 1 | United States, Australia, Canada, South Korea | À vérifier | |
| CyclophosphamideThis randomized phase II trial studies how well paclitaxel with or without carboplatin and/or bevacizumab followed by doxorubicin and cyclophosphamide works in treating patients with breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as paclitaxel, carboplatin, doxorubicin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Bevacizumab may stop the growth of tumor cells by blocking blood flow to the tumor. Giving chemotherapy together with bevacizumab before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. | SEP | Phase 2 | À vérifier | United States | À vérifier |
| anito-celThe goal of this clinical study is to learn more about the study drug Anitocabtagene autoleucel (anito-cel), and its safety, tolerability, dosing, and preliminary effectiveness in participants with generalized myasthenia gravis (GMG). Anito-cel is a B-cell maturation antigen (BCMA)-directed CAR-T cell therapy. The primary objective of this study is to assess the safety profile, including any dose-limiting toxicity (DLT) and identification of a maximum tolerated dose (MTD) (if applicable), to support selection of the recommended Phase 2 dose (RP2D) of anito-cel when administered to participants with GMG. | Myasthénie | Phase 1 | Thérapie cellulaire | United States | À vérifier |
| brexucabtagene autoleucelThe primary objective of this study is to evaluate the safety and tolerability of brexucabtagene autoleucel (KTE-X19) in adults with relapsed/refractory chronic lymphocytic leukemia (r/r CLL) and small lymphocytic lymphoma (r/r SLL) who have received at least 2 prior lines of treatment, one of which must include a Bruton's tyrosine kinase (BTK) inhibitor. After the end of KTE-C19-108, participants who received an infusion of brexucabtagene autoleucel will complete the remainder of the 15-year follow-up assessments in a separate Long-term Follow-up study, KT-US-982-5968 (NCT05041309). | SEP | Phase 1 | Immunomodulation | United States, Italy | À vérifier |
Essais cliniques
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| brexucabtagene autoleucel | SEP | Phase 1 | NCT03624036 | ZUMA-8 — Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | TERMINATED |
| anito-cel | Myasthénie | Phase 1 | NCT06626919 | Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases | RECRUITING |
| Cyclophosphamide | SEP | Phase 2 | NCT02629809 | Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING |
| KITE-363 | Lupus | Phase 1 | NCT07038447 | A Study of KITE-363 in Participants With Refractory Autoimmune Diseases | ENROLLING_BY_INVITATION |
| Cyclophosphamide | Sclérose latérale amyotrophique | Phase 2 | NCT07834450 | CORTEX-ALS — Efficacy and Safety of Cyclophosphamide in Amyotrophic Lateral Sclerosis | NOT_YET_RECRUITING |
| Cyclophosphamide | Cancer | Phase 2 | NCT07524530 | Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers | NOT_YET_RECRUITING |
| KITE-363 | Myasthénie | Phase 1 | NCT07304154 | HERMOSA-2 — Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment | RECRUITING |
| Cyclophosphamide | Lupus | NA | NCT03492255 | CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid | TERMINATED |
Publications
26| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Fludarabine | Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma. | Blood advances | ||
| Fludarabine | Tailored conditioning for hematopoietic stem cell transplantation in children with Mendelian susceptibility to mycobacterial disease: A tale of two pathways for IFN-γ and IL-12 defects. | Journal of human immunity | ||
| Fludarabine | Targeting IMPDH to inhibit SAMHD1 in -rearranged leukaemia. | Cell cycle (Georgetown, Tex.) | ||
| Cyclophosphamide | A systematic assessment of the short- and long-term effects of commonly used breast cancer chemotherapeutics on the gut microbiome‒blood‒brain axis of female mice. | Gut microbes | ||
| Cyclophosphamide | Investigating and validating the molecular mechanisms of lipid metabolism regulation in myasthenia gravis development based on single-cell, bulk transcriptomics, and RT-qPCR. | Autoimmunity | ||
| Cyclophosphamide | Multi-omics reveals the mechanism of Rehmannia glutinosa Libosch. Processed with Amomum villosum Lour. in treating blood deficiency syndrome. | Journal of ethnopharmacology | ||
| Fludarabine | A phase II study of low dose melphalan with thiotepa and fludarabine as preparative regimen for alternative donor transplantation. | Leukemia & lymphoma | ||
| Fludarabine | The discovery of potent and selective N-modified adenosine derivatives as effective chemotherapeutic agents to overcome p53-dependent drug resistance in cancer and HPIV-3/AdV5 respiratory tract infections. | Bioorganic chemistry | ||
| Cyclophosphamide | SP-3 Ameliorates Established Cyclophosphamide-Induced Liver Injury and Is Associated with PPAR-Related Transcriptional and Lipid-Metabolic Changes. | International journal of molecular sciences | ||
| Cyclophosphamide | Amyloidosis and Thoracic Aortic Disease: A Scoping Review. | Journal of clinical medicine | ||
| Cyclophosphamide | [Sustained complete remission achieved with tofacitinib in a refractory T-cell large granular lymphocytic leukemia]. | La Revue de medecine interne | ||
| Cyclophosphamide | Nonmyeloablative and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation in sickle cell disease: a narrative review of safety, engraftment, and graft-versus-host-disease outcomes in adults and high-risk populations. | Bone marrow transplantation | ||
| Cyclophosphamide | Alleviation effect of Potentilla anserina polysaccharides on intestinal barrier dysfunction and its underlying mechanism. | International journal of biological macromolecules | ||
| Cyclophosphamide | Real-world outcomes of BrECADD therapy in advanced-stage classical Hodgkin lymphoma: A multicentre retrospective study. | British journal of haematology | ||
| Fludarabine | Efficacy and safety of mitoxantrone hydrochloride liposome/ thiotepa/ busulfan/fludarabine (MTBF) conditioning regimen for salvage allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory acute myeloid leukemia: A single - Arm prospective clinical trial. | Cell transplantation | ||
| Cyclophosphamide | Salvage ultra-low-dose radiotherapy for conjunctival mantle cell lymphoma - a case report and literature review. | Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology | ||
| Cyclophosphamide | Application Timing-Dependent Impact of Donor Source on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma. | Hematological oncology | ||
| Cyclophosphamide | Breakthrough reactions in pediatric chemotherapeutic desensitization: Outcomes and associated risk factors. | Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology | ||
| Cyclophosphamide | Multi-omics integration reveals that pterostilbene ameliorates cyclophosphamide-induced liver injury the gut-liver axis by inhibiting inflammation and oxidative stress. | Food & function | ||
| Fludarabine | Novel pathological genetic variant associated with DOCK8 deficiency: case report with successful hematopoietic stem cell transplantation. | Allergologia et immunopathologia | ||
| Fludarabine | Precision myeloablation with TDM-guided busulfan in pediatric primary immunodeficiencies: a real-world study of 28 patients. | Translational pediatrics | ||
| Cyclophosphamide | Dermatomyositis With Necrotizing Vasculitis, Pulmonary Arterial Hypertension, and Extensive Calcinosis Following Delayed Diagnosis. | Cureus | ||
| Fludarabine | Radioimmunotherapy as a targeted strategy of reduced-intensity conditioning for allogeneic transplantation in leukemia. | Frontiers in oncology | ||
| Fludarabine | Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT. | Bone marrow transplantation | ||
| Cyclophosphamide | Refractory Malignant Pericardial Effusion as the Initial Presentation of Early T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma. | Cureus | ||
| Cyclophosphamide | Incidence and impact of odontogenic infection-related febrile episodes during perioperative doxorubicin-cyclophosphamide or docetaxel-cyclophosphamide chemotherapy for breast cancer. | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer |